Helix begins patient enrollment for thirteenth group in Polish Phase I/II trial of L-DOS47 to treat lung cancer
L-DOS47 is the company’s first immunoconjugate-based drug candidate being developed based upon its new DOS47 technology, which is designed to use an innovative approach to modify the microenvironmental